# Sex differences in in vitro and in vivo glaucoma models may predict gender specific dose adjustment needs

> **NIH NIH R01** · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2021 · $147,667

## Abstract

PROJECT SUMMARY
One of the most definite epidemiological characteristics of primary open angle glaucoma (POAG) is that, its
incidence shows a strong sex-related difference. Nitric oxide (NO) is directly implicated in the regulation of
intraocular pressure (IOP) in glaucoma. Our laboratory is currently working on design, synthesis and testing of
a novel hybrid class of NO donors to lower IOP with neuroprotective activity in rodent models. Several
epidemiological studies have suggested that estrogen levels correlate positively to increased retinal blood
circulation, increased NO synthesis and negatively with intra ocular pressure (IOP) levels. Estrogen increases
the activity of endothelial-based nitric oxide synthase (NOS) and therefore regulates smooth muscle tone and
vascular resistance. Since estrogen receptors are located in the trabecular meshwork, ciliary body and the
outflow system of the eye, it might potentially influence IOP by regulating both aqueous humor production and
outflow. Consequently, there may be gender-dependent differential response to anti-glaucoma drugs especially
to that simultaneously deliver NO along with antioxidant activity which interfere with estrogen signaling in men
and women. The goal of this project is to determine the gender specific effects of the NO donating-
antioxidant hybrid compounds on the trabecular meshwork (TM) cell’s anti-oxidant enzyme status,
extracellular matrix composition, estrogen regulating enzyme levels and on the overall IOP lowering
activity.
We have synthesized a novel multifunctional hybrid anti-oxidant and NO donating compound SA-2 as well as
several other novel highly antioxidant derivatives of SA-2 compound. Our published results ensued from this
project demonstrated that a single eye drop of a nano encapsulated suspension of SA-2 lowered IOP by 50% in
mouse as well as in rat glaucoma model (in both males and females). Additionally, compound SA-2 is
neuroprotective ex vivo in hypoxia treated retinal explants and in the in vivo IOP-independent optic nerve crush
(ONC) model performed in female mice. In our preliminary result using human trabecular meshwork (hTM) cells,
we found that there is a gender dependent difference in the cytoprotective activity of SA-2 at 1mM dose. We
further found that, the female mice respond differently than male mice when subjected to ONC injury.
Specifically, for this NIH supplement application, we propose to use primary human hTM cell derived both from
female and male donors (specific aim 1) as well as in glaucomatous TM tissues from three animal groups:
females, males and ovariectomized (OVX) females, in which OVX procedure models a postmenopausal state
(specific aim 2). We hypothesize that, compound SA-2 and its novel analog SA-10 will have differential cellular
and molecular activities depending on the gender and estrogen-related signaling. Successful completion of the
proposed studies will have an implication for developing novel therapeutics for glaucoma...

## Key facts

- **NIH application ID:** 10333877
- **Project number:** 3R01EY029823-02S1
- **Recipient organization:** UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
- **Principal Investigator:** Suchismita Acharya
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $147,667
- **Award type:** 3
- **Project period:** 2020-09-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10333877

## Citation

> US National Institutes of Health, RePORTER application 10333877, Sex differences in in vitro and in vivo glaucoma models may predict gender specific dose adjustment needs (3R01EY029823-02S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10333877. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*